Arno Therapeutics ARNI Stock
Arno Therapeutics Price Chart
Arno Therapeutics ARNI Financial and Trading Overview
| Arno Therapeutics stock price | 0.0001 USD |
| Previous Close | 0.0001 USD |
| Open | 0.0001 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0001 - 0.0001 USD |
| 52 Week Range | 0.0001 - 0.0021 USD |
| Volume | 5K USD |
| Avg. Volume | 162 USD |
| Market Cap | 177.66K USD |
| Beta (5Y Monthly) | 5.599295 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ARNI Valuation Measures
| Enterprise Value | -2114056 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.191 |
Trading Information
Arno Therapeutics Stock Price History
| Beta (5Y Monthly) | 5.599295 |
| 52-Week Change | -95.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.0021 USD |
| 52 Week Low | 0.0001 USD |
| 50-Day Moving Average | 0.00138 USD |
| 200-Day Moving Average | 0.0018763975 USD |
ARNI Share Statistics
| Avg. Volume (3 month) | 162 USD |
| Avg. Daily Volume (10-Days) | 499 USD |
| Shares Outstanding | 49.35M |
| Float | 15.03M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 2.68% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2015 |
| Most Recent Quarter (mrq) | September 30, 2016 |
| Next Fiscal Year End | December 31, 2016 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -500.040% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -11055458 USD |
| Net Income Avi to Common (ttm) | -13695440 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.12M USD |
| Total Cash Per Share (mrq) | 0.04 USD |
| Total Debt (mrq) | 5.09K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.524 |
| Book Value Per Share (mrq) | -0.119 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7617789 USD |
| Levered Free Cash Flow (ttm) | -3947752 USD |
Profile of Arno Therapeutics
| Country | United States |
| State | NJ |
| City | Flemington |
| Address | 200 Route 31 North |
| ZIP | 08822 |
| Phone | 862 703 7170 |
| Website | https://www.arnothera.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Q&A For Arno Therapeutics Stock
What is a current ARNI stock price?
Arno Therapeutics ARNI stock price today per share is 0.0001 USD.
How to purchase Arno Therapeutics stock?
You can buy ARNI shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arno Therapeutics?
The stock symbol or ticker of Arno Therapeutics is ARNI.
Which industry does the Arno Therapeutics company belong to?
The Arno Therapeutics industry is Biotechnology.
How many shares does Arno Therapeutics have in circulation?
The max supply of Arno Therapeutics shares is 1.78B.
What is Arno Therapeutics Price to Earnings Ratio (PE Ratio)?
Arno Therapeutics PE Ratio is now.
What was Arno Therapeutics earnings per share over the trailing 12 months (TTM)?
Arno Therapeutics EPS is -0.01 USD over the trailing 12 months.
Which sector does the Arno Therapeutics company belong to?
The Arno Therapeutics sector is Healthcare.